Blood Cell Count Biomarkers Predicting Efficacy of Pembrolizumab as Second-line Therapy for Advanced Urothelial Carcinoma.
Kadono Y, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Kamijima T, Seto C, Takano A, Yotsuyanagi S, Nakagawa R, Miyagi T, Aoyama S, Asahi H, Fukuda R, Mizokami A.
Kadono Y, et al. Among authors: nohara t.
Anticancer Res. 2021 Mar;41(3):1599-1606. doi: 10.21873/anticanres.14921.
Anticancer Res. 2021.
PMID: 33788755